Philipp Jost studied medicine at the Technical University of Munich and completed his doctorate degree at the Imperial College London in 1999 (summa cum laude), where he investigated gene therapy of Cystic Fibrosis in the laboratory of Prof. Coutelle. In 2003, he joined the group of Prof. Ruland at the TUM for his postdoctoral research, which centered around molecular analysis of T-cell development. As a scholar of the Mildred Scheel Foundation, he continued his postdoctoral training in the laboratory of Prof. Strasser at the Walter and Eliza Hall Institute, Melbourne, where he focused on the role of pro-survival Bcl-2 family members in cancer. In 2010, Philipp Jost returned to the TUM and started his own research group on “Mechanism of Tumor Cell Survival” as a Max Eder-research fellow. In 2011 he completed his clinical specialization at the university hospital of the TUM, where he was also granted a professorship in 2018.
The aim of our research group “Molecular Oncology” is to elucidate the basic principles restricting cell death in cancer and their relevance for clinical translation. We study the regulation of cell death in healthy and malignant cells. The focus of our work is the understanding of cell death mechanisms and their regulation in tumor cell initiation, tumor maintenance and resistance mechanisms. As model systems we employ genetic deletion or pharmacologic inhibition of individual cell death regulating proteins in various murine tumor models. In addition, we also employ spatiotemporal deletion of individual cell death regulating proteins for characterization of their role in tumor initiation and maintenance. Moreover, we place a specific focus on the rapid translation of murine data into patients. To accomplish this goal, we utilize a broad array of techniques from molecular biology, cell biology, mouse genetics and biochemistry in combination with a strong medical background. Our research covers a broad field of oncological disciplines, ranging from various hematological diseases over to different kinds of lung cancer. Due to the close interaction between scientists and clinicians we can realize translational cancer research in our daily work.
Written applications including CV are welcome and should be forwarded by e-mail to Prof. Dr. Philipp Jost.
- 2016 - Faculty Member at the German Consortium for Translational Oncology (DKTK)
- 2011 - Fellowship “Translational Research Training Program” (TRTH) by EHA and ASH
- 2010 - Editorial Board Member at Frontiers in Molecular and Cellular Oncology
- 2010 - Max Eder Research Fellow, Deutsche Krebshilfe
- 2007 - Postdoc Fellowship by Mildred Scheel Foundation
- 2001 - European Cystic Fibrosis Fellowship, European Society of Cystic Fibrosis
- 2000 - Best Basic Science Abstract, 13th Intl. Congress for Cystic Fibrosis, Stockholm
- Jost PJ, Höckendorf U. Necroinflammation emerges as a key regulator of hematopoiesis in health and disease. Cell Death and Differentiation, 2018.
- Lawlor KE*, Feltham R*, Yabal M*, Conos SA, Chen KW, Ziehe S, Grass C, Zhan Y, Nguyen T, Hall C, Vince AJ, Chatfield SM, D'Silva DB, Pang KC, Schroder K, Silke J, Vaux DL, Jost PJ*, Vince JE*. XIAP Loss Triggers RIPK3 and Caspase-8-Driven IL-1beta Activation and Cell Death as a Consequence of TLR-MyD88-Induced cIAP1-TRAF2 Degradation. Cell Rep, 2017.
- Höckendorf, U., Yabal, M., Herold, T., Munkhbaatar, E., Rott, S., Jilg, S., Kauschinger, J., Magnani, G., Reisinger, F., Heuser, M., Kreipe, H., Sotlar, K., Engleitner, T., Rad, R., Weichert, W., Peschel, C., Ruland, J., Heikenwalder, M., Spiekermann, K., Slotta-Huspenina, J., Groß, O., Jost, P.J. RIPK3 Restricts Myeloid Leukemogenesis by Promoting Cell Death and Differentiation of Leukemia Initiating Cells. Cancer Cell (2016).
- Yabal M, Müller N, Adler H, Knies N, Groß CJ, Damgaard RB, Kanegane H, Ringelhan M, Kaufmann T, Heikenwälder M, Strasser A, Groß O, Ruland J, Peschel C, Gyrd-Hansen M, Jost PJ. XIAP Restricts TNF- and RIP3-Dependent Cell Death and Inflammasome Activation. Cell Rep, 2014.
- Damgaard RB*, Nachbur U*, Yabal Y*, Wong WL, Fiil BK, Kastirr M, Rieser E, Rickard JA, Bankovacki A, Peschel C, Ruland J, Bekker-Jensen S, Mailand N, Kaufmann T, Strasser A, Walczak H, Silke J, Jost PJ§#, Gyrd-Hansen M§# (§: Senior Author; #: Corresponding Author). The ubiquitin ligase XIAP recruits LUBAC for NOD2 signalling in inflammation and innate immunity, Mol Cell, 2012.
- Vikstrom I., Carotta S., Luthje K., Peperzak V., Jost PJ., Glaser S., Busslinger M., Bouillet P., Strasser A., Nutt SL., Tarlinton DM., Mcl-1 is Essential for Germinal Center Formation and B cell Memory, Science 2010.
- Jost PJ., Grabow, S., Gray, D., McKenzie, MD., Nachbur, U., Huang, DCS., Bouillet, P., Thomas, HE., Borner, C., Silke, J., Strasser, A., Kaufmann, T. XIAP discriminates between type I and type II FAS-induced apoptosis. Nature, 2009.